Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.41 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | PRKAG1 | P54619 | 2/20 | 0.33 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.33 |
| ▸ | PRKAB1 | Q9Y478 | 2/20 | 0.33 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.33 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.32 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.32 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.32 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.32 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12215466 | 0.89 | CYP2C9 (0.44) | CYP2C9CYP3A4CYP2D6CYP1A2CYP2C8 | |
| SCHEMBL1762967 | 0.88 | CYP2C9 (0.43) | CYP2C9CYP3A4CYP2D6CYP1A2CYP2C8 | |
| Potassium Ion SCHEMBL1763584 | 0.88 | CYP2C9 (0.43) | CYP2C9CYP3A4CYP2D6CYP1A2CYP2C8 | |
| SCHEMBL10326256 | 0.85 | CYP2C9 (0.47) | CYP2C9CYP3A4CYP2D6CYP1A2CYP2C8 | |
| SCHEMBL1472698 | 0.85 | CYP2C9 (0.61) | CYP2C9CYP3A4CYP2D6CYP1A2CYP2C8 | |
| SCHEMBL12238398 | 0.85 | CYP2C9 (0.47) | CYP2C9CYP3A4CYP2D6CYP1A2CYP2C8 | |
| Water SCHEMBL1733706 | 0.84 | CYP2C9 (0.60) | CYP2C9CYP3A4CYP2D6CYP1A2CYP2C8 | |
| SCHEMBL29616351 | 0.84 | CYP2C9 (0.47) | CYP2C9CYP3A4CYP2D6CYP1A2CYP2C8 | |
| SCHEMBL1550197 | 0.84 | CYP2C9 (0.47) | CYP2C9CYP3A4CYP2D6CYP1A2CYP2C8 | |
| SCHEMBL7063069 | 0.84 | CYP2C9 (0.41) | CYP2C9CYP3A4CYP2D6CYP1A2CYP2C8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190328900-A1 | ANTIBODY-DRUG CONJUGATES AND THERAPEUTIC METHODS USING THE SAME | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2019-10-31 | — | — | US | disclosed |
| EP-2978763-B1 | 2-KETO AMIDE DERIVATIVES AS HIV ATTACHMENT INHIBITORS | VIIV HEALTHCARE UK (NO 5) LTD (GB) | 2018-03-07 | — | — | EP | disclosed |
| EP-2975038-B1 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | VIIV HEALTHCARE UK(NO 4) LTD (GB) | 2017-07-12 | — | — | EP | disclosed |
| US-9655888-B2 | Tricyclic alkene derivatives as HIV attachment inhibitors | VIIV Healthcare UK (No.5) Limited (GB) | 2017-05-23 | — | — | US | disclosed |
| US-9655888-B2 | Tricyclic alkene derivatives as HIV attachment inhibitors | VIIV Healthcare UK (No.5) Limited (GB) | 2017-05-23 | — | — | US | disclosed |
| US-9586957-B2 | 2-keto amide derivatives as HIV attachment inhibitors | VIIV Healthcare UK (No.5) Limited (GB) | 2017-03-07 | — | — | US | disclosed |
| US-9586957-B2 | 2-keto amide derivatives as HIV attachment inhibitors | VIIV Healthcare UK (No.5) Limited (GB) | 2017-03-07 | — | — | US | disclosed |
| EP-2895472-B1 | Tricyclic alkene derivatives as HIV attachment inhibitors | VIIV HEALTHCARE UK NO 5 LTD (GB) | 2016-11-23 | — | — | EP | disclosed |
| US-20160214998-A1 | NOVEL COMPOSITIONS USEFUL FOR INHIBITING HIV-1 INFECTION AND METHODS USING SAME | DREXEL UNIVERSITY (US) | 2016-07-28 | — | — | US | disclosed |
| US-20160207918-A1 | SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2016-07-21 | — | — | US | disclosed |
| WO-2004019944-A1 | 2-HYDROXY-6-PHENYLPHENANTHRIDINES AS PDE-4 INHIBITORS | ALTANA PHARMA AG (DE) | 2004-03-11 | — | — | WO | disclosed |
| WO-2004014380-A1 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-02-19 | — | — | WO | disclosed |
| US-20040023982-A1 | Antiviral azaindole derivatives | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2004-02-05 | — | — | US | disclosed |
| EP-1363705-A1 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-11-26 | — | — | EP | disclosed |
| US-20030207910-A1 | Treatment of HIV and AIDS | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2003-11-06 | — | — | US | disclosed |
| US-6632819-B1 | HIV and AIDS | BRISTOL-MYERS SQUIBB COMPANY | 2003-10-14 | — | — | US | disclosed |
| US-20030069266-A1 | Aids therapy | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2003-04-10 | — | — | US | disclosed |
| US-6476034-B2 | AIDS THERAPY | BRISTOL-MYERS SQUIBB COMPANY | 2002-11-05 | — | — | US | disclosed |
| US-20020119982-A1 | Antiviral azaindole derivatives | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2002-08-29 | — | — | US | disclosed |
| WO-2002062423-A1 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119982-A1 | Antiviral azaindole derivatives | ZC3HAV1, MAVS, AZI2 | CYP2C9 3477/4885CYP3A4 491/4885CYP2D6 1648/4885 |
| US-20160214998-A1 | NOVEL COMPOSITIONS USEFUL FOR INHIBITING HIV-1 INFECTION AND METHODS USING SAME | CCL5, CCR5, CXCL10 | CYP2C9 4831/4885CYP3A4 4235/4885CYP2D6 4602/4885 |
| US-20030069266-A1 | Aids therapy | ENTPD5, CCR5, ITPA | CYP2C9 2580/4885CYP3A4 363/4885CYP2D6 969/4885 |
| US-20160207918-A1 | SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | PREP, PEPD, DNPEP | CYP2C9 1411/4885CYP3A4 175/4885CYP2D6 421/4885 |
| US-20040023982-A1 | Antiviral azaindole derivatives | ZC3HAV1, MAVS, EIF2AK2 | CYP2C9 3466/4885CYP3A4 589/4885CYP2D6 1508/4885 |
| US-20030207910-A1 | Treatment of HIV and AIDS | CD4, CCR5, IDO1 | CYP2C9 1831/4885CYP3A4 138/4885CYP2D6 936/4885 |
| US-20190328900-A1 | ANTIBODY-DRUG CONJUGATES AND THERAPEUTIC METHODS USING THE SAME | CD4, ABCB1, FCGR3B | CYP2C9 1024/4885CYP3A4 846/4885CYP2D6 300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.